15 on COVID-19 03/23/2020

Activity Preview

Welcome to the inaugural episode of APhA’s 15 on COVID-19 series, designed to provide you with the answers you need to educate yourself, your colleagues, and your patients about COVID-19. In today’s episode, we will be exploring the role of two older antimalarial drugs in COVID-19:

As the COVID-19 pandemic progresses, people everywhere are looking for potential treatments to stop the spread of the disease, treat the symptoms of the disease , and reduce the mortality of COVID-19. One drug that has rapidly captured the world’s attention is chloroquine, and it’s close relative, hydroxychloroquine. This may seem strange at first glance – after all, chloroquine and hydroxychloroquine are antimalarial medications. What utility could they possibly have in treating COVID-19, a disease caused by a novel strain of coronavirus, SARS-CoV-2? Join APhA experts as we explore the science behind the drug, and attempt to separate truth from fiction in this rapidly changing series of events.

Learning Objectives

  • Describe the hypothesized mechanisms of quinolone antimalarials in the treatment of COVID-19

Activity type: Knowledge-based
Target Audience: Pharmacists and Technicians
Learning Level: 2

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 0.25 contact hour of CPE credit (0.025 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-159-H01-P/T

To obtain credit for completing 15 on COVID-19 03/23/2020,  participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.    

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: March 23, 2020
Expiration date: March 23, 2021

Development

15 on COVID-19 03/23/2020 is an activity for pharmacists and technicians developed by the American Pharmacists Association. © 2020 American Pharmacists Association

Disclosures

Daniel Zlott, PharmD, BCOP and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures

Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association. 

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-20-159-H01-P 0.025 CEUs March 23, 2020 - March 23, 2021
ACPE# 0202-0000-20-159-H01-T 0.025 CEUs March 23, 2020 - March 23, 2021